Background

Cancer is a leading cause of morbidity worldwide, with incidence continuing to rise as populations age and diagnostic testing becomes more widespread. Biomarker-based immunoassays are central to modern oncology diagnostics, supporting disease detection, monitoring, and assessment of treatment response across a wide range of cancer indications. As testing volumes increase, there is a growing need for reliable, well-characterised reagents to ensure consistent assay performance.

The Native Antigen Company is a global supplier of high-quality biological reagents for in vitro diagnostic and life science applications. Building on our established expertise in recombinant protein technologies, we are expanding our portfolio into cancer biomarkers to support assay development and research workflows. Using proven recombinant expression systems and scalable manufacturing capabilities, we provide consistent cancer antigens designed to enable reproducible results and dependable supply, helping customers develop, validate, and maintain robust diagnostic assays.